Actively Recruiting
COVID-19 International Drug Pregnancy Registry
Led by Pregistry · Updated on 2025-09-26
2000
Participants Needed
1
Research Sites
304 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is to evaluate obstetric, neonatal, and infant outcomes among women treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 from the first day of the last menstrual period (LMP) to end of pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP.
CONDITIONS
Official Title
COVID-19 International Drug Pregnancy Registry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pregnant or recently pregnant (up to 30 days after the end of pregnancy) at time of enrollment
- Age 18 years or older at time of enrollment
- Diagnosed with mild to severe COVID-19 during pregnancy
- Treated for COVID-19 with at least one specified medication during pregnancy, or hospitalized without receiving specific COVID-19 drug treatments
- Resident of a country with appropriate Central Institutional Review Board or Ethics Committee approval or exemption
- Signed informed consent and submitted baseline COVID-19 medication information
You will not qualify if you...
- Under 18 years of age
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Pregistry
Los Angeles, California, United States, 90045
Actively Recruiting
Research Team
C
Cheryl Renz, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here